Related references
Note: Only part of the references are listed.Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia
Sheng-hong Du et al.
FRONTIERS IN IMMUNOLOGY (2021)
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
Markus Klein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Proteasome Inhibitor Drugs
Lloyd D. Fricker
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders
Breanna L. Zerfas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
David J. Sherman et al.
MOLECULES (2020)
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Shigeki Ito
CANCERS (2020)
Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation
Mariella Bockstahler et al.
CIRCULATION (2020)
LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease
Deepak Bhattarai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Covalent inhibitors: back on track?
Matthias Gehringer
FUTURE MEDICINAL CHEMISTRY (2020)
The impact of regional astrocyte interferon-γ signaling during chronic autoimmunity: a novel role for the immunoproteasome
Brandon C. Smith et al.
JOURNAL OF NEUROINFLAMMATION (2020)
Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
Surya Kant Tripathi et al.
PHARMACOLOGICAL RESEARCH (2020)
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
Michael Basler et al.
GENES AND IMMUNITY (2020)
Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides
Wenhu Zhan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Covalent Inhibition in Drug Discovery
Avick Kumar Ghosh et al.
CHEMMEDCHEM (2019)
Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes
Roberta Ettari et al.
CHEMMEDCHEM (2019)
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau et al.
PHARMACOLOGICAL REVIEWS (2019)
Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability
Ena Ladi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
Andrea Scarpino et al.
MOLECULES (2019)
Immunoproteasome Inhibition Selectively Kills Human CD14+ Monocytes and as a Result Dampens IL-23 Secretion
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2019)
The PSMA8 subunit of the spermatoproteasome is essential for proper meiotic exit and mouse fertility
Laura Gomez-H et al.
PLOS GENETICS (2019)
Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
Bo-Tao Xin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Restricted Expression of the Thymoproteasome Is Required for Thymic Selection and Peripheral Homeostasis of CD8+ T Cells
Utano Tomaru et al.
CELL REPORTS (2019)
A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors
Eva Shannon Schiffrer et al.
MEDCHEMCOMM (2019)
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells
Roberta Ettari et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome
Elodie Bosc et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis
Nadine Althof et al.
EMBO MOLECULAR MEDICINE (2018)
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Jun Li et al.
KIDNEY INTERNATIONAL (2018)
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park et al.
TRANSLATIONAL RESEARCH (2018)
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
Michael Basler et al.
EMBO REPORTS (2018)
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenannide)
Henry W. B. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome
Michael Basler et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Covalent inhibitors design and discovery
Stephane De Cesco et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production
Haijie Liu et al.
FASEB JOURNAL (2017)
Activity-based probes for the multicatalytic proteasome
David S. Hewings et al.
FEBS JOURNAL (2017)
ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response
Ru-Tao Liu et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit
Henry W. B. Johnson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes
Ruda de Luna Almeida Santos et al.
NATURE COMMUNICATIONS (2017)
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
Philipp M. Cromm et al.
ACS CENTRAL SCIENCE (2017)
LOW NEUROTOXICITY OF ONX-0914 SUPPORTS THE IDEA OF SPECIFIC IMMUNOPROTEASOME INHIBITION AS A SIDE-EFFECT-LIMITING, THERAPEUTIC STRATEGY
Laura von Brzezinski et al.
EUROPEAN JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY (2017)
Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome
Haissi Cui et al.
CHEMBIOCHEM (2017)
Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (5i) Subunit of the Immunoproteasome
Izidor Sosic et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Immunoproteasome 5i-Selective Dipeptidomimetic Inhibitors
Pradeep K. Singh et al.
CHEMMEDCHEM (2016)
A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit 5i
Eva M. Huber et al.
EMBO JOURNAL (2016)
Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay
Gerjan de Bruin et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice
Esilida Sula Karreci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
Jil Schrader et al.
SCIENCE (2016)
A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome
Eva M. Huber et al.
NATURE COMMUNICATIONS (2016)
Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine
Christian Dubiella et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft-versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen Disparate Murine Model
Jenny Zilberberg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors
Eva M. Huber et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib
Wayne Harshbarger et al.
STRUCTURE (2015)
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924
Denise Niewerth et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Assembly of the 20S proteasome
Mary J. Kunjappu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening
Vinod Kasam et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis
Michael Basler et al.
EMBO MOLECULAR MEDICINE (2014)
Characterization of the Testis-specific Proteasome Subunit α4s in Mammals
Hiroyuki Uechi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
Gerjan de Bruin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The unique functions of tissue-specific proteasomes
Andrea Kniepert et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome
Hao Fan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Acetylation-Mediated Proteasomal Degradation of Core Histones during DNA Repair and Spermatogenesis
Min-Xian Qian et al.
CELL (2013)
Boronic Acid-Containing Proteasome Inhibitors: Alert to Potential Pharmaceutical Bioactivation
Austin C. Li et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2013)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Non-Covalent Proteasome Inhibitors
Julia Kaffy et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Thymoproteasome subunit-β5T generates peptide-MHC complexes specialized for positive selection
Yan Xing et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cysteine protease inhibition by nitrile-based inhibitors: a computational study
Matthew G. Quesne et al.
FRONTIERS IN CHEMISTRY (2013)
Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
Utkarsh Painuly et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2013)
Hydroxyureas as Noncovalent Proteasome Inhibitors
Nerea Gallastegui et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Eva Maria Huber et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
H. Travis Ichikawa et al.
ARTHRITIS AND RHEUMATISM (2012)
Covalent and non-covalent reversible proteasome inhibition
Philipp Beck et al.
BIOLOGICAL CHEMISTRY (2012)
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice
M. Wehenkel et al.
BRITISH JOURNAL OF CANCER (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells
Lalit Kumar Sharma et al.
CHEMBIOCHEM (2012)
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development
Melissa Ann Graewert et al.
CHEMICAL COMMUNICATIONS (2012)
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice
Y. Nagayama et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Why the Structure but Not the Activity of the Immunoproteasome Subunit Low Molecular Mass Polypeptide 2 Rescues Antigen Presentation
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2012)
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors
Simone Cenci et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Iana M. Serafimova et al.
NATURE CHEMICAL BIOLOGY (2012)
Selective protein degradation in cell signalling
Han Liu et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2012)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Proteasome Activators
Beth M. Stadtmueller et al.
MOLECULAR CELL (2011)
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Jacques Neefjes et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Christopher Blackburn et al.
BIOCHEMICAL JOURNAL (2010)
Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2010)
Molecular Basis of the Selectivity of the Immunoproteasome Catalytic Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics Simulations
Beilei Lei et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2010)
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules
Benoit Guillaume et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
Matthew Britton et al.
CHEMISTRY & BIOLOGY (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
Michael Groll et al.
NATURE (2008)
Intermediate-type 20 S proteasomes in HeLa cells: Asymmetric subunit composition, diversity and adaptation
Nicola Klare et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Regulation of CD8+ T cell development by thymus-specific proteasomes
Shigeo Murata et al.
SCIENCE (2007)
LMP2-specific inhibitors: Chemical genetic tools for proteasome biology
Yik Khuan (Abby) Ho et al.
CHEMISTRY & BIOLOGY (2007)
Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites
T Pekol et al.
DRUG METABOLISM AND DISPOSITION (2005)
The structure of the mammalian 20S proteasome at 2.75 Å resolution
M Unno et al.
STRUCTURE (2002)
The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release
A Köhler et al.
MOLECULAR CELL (2001)
A gated channel into the proteasome core particle
M Groll et al.
NATURE STRUCTURAL BIOLOGY (2000)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
Share Paper
